Presentation of Ecoxtract
Located at 224 Avenue de la Dordogne in Dunkerque, Minakem operates a cosmetic lab and pharmaceutical manufacturing facility in France’s Hauts-de-France region. With 150m3 reaction capacity, the site delivers:
- Multi-ton scale production up to 300 tons
- Specialized steroid and prazole synthesis units
- Micronization and injectable grade capabilities
- FDA, ANSM and PMDA approved manufacturing
The Dunkerque facility serves markets across the US, EU, China and Japan through cGMP-compliant synthesis of active pharmaceutical ingredients.
Ecoxtract newsfeed
- Ecoxtract has not yet been verified. The newsfeed is disabled.
Detailed presentation of Ecoxtract
A leading pharmaceutical facility in northern France
Ecoxtract operates as a cosmetic lab and pharmaceutical manufacturing facility from its base in Dunkerque, Hauts-de-France. The company has established itself as a significant player in the European pharmaceutical sector since its founding.
Manufacturing capabilities and expertise
With a total reaction volume of 178m³, Ecoxtract manages large-scale production operations. The facility specializes in organic synthesis processes, handling between 2-4 steps and producing up to 300 tons of commercial APIs.
Specialized production areas
- Dedicated steroid synthesis unit
- Micronization trains for precise particle size control
- Injectable grade production facilities
Product portfolio and development
The company focuses on producing high-quality pharmaceutical ingredients, including:
- Esomeprazole
- Omperazole
- Budesonide
Strategic location and market access
Located at 224 Avenue de la Dordogne in Dunkerque, the facility benefits from excellent logistics connections to major European markets. This northern France location provides direct access to shipping routes through the Port of Dunkirk, facilitating global distribution.
Regulatory standards and compliance
Ecoxtract maintains international regulatory approvals from:
- FDA (USA) – 2018
- ANSM (France) – 2017
- PMDA (Japan) – 2016
Recent developments and growth
A €14.5M investment in 2018 expanded the facility’s production capacity, adding 28m³ of reaction volume. This expansion supports the company’s growing presence in global pharmaceutical markets, with regulatory filing capabilities across the US, China, EU, and Japan.
Services provided by Ecoxtract
Below you will find the services provided by Ecoxtract. Like each cosmetic lab on the platform, the services are manually registered by the providing company.
- Ecoxtract has no service catalogue on cosmetic-labs.com.
Gallery and medias
- Ecoxtract has not yet posted any media. There is no gallery yet.
Frequent questions
What products does Ecoxtract manufacture?
Ecoxtract produces active pharmaceutical ingredients (APIs) through:
- Core product lines:
- Esomeprazole
- Omperazole
- Budesonide
- Manufacturing processes:
- Organic synthesis (2-4 steps)
- Stereoselective syntheses
- Steroid synthesis
- Production capacity:
- 150m³ reaction volume
- 28m³ development volume
- Up to 300 tons for commercial APIs
What are Ecoxtract's technical capabilities?
The facility operates with the following technical infrastructure:
- Production equipment:
- Micronization trains
- Injectable grade manufacturing lines
- Dedicated steroid production unit
- Facility investments:
- €14.5M expansion in 2018
- 28m³ additional production capacity
- 26m³ freed production volume
- Quality systems:
- GMP manufacturing protocols
- Regulatory compliance procedures
- Quality control laboratories
Which markets does Ecoxtract serve with regulatory approvals?
Ecoxtract maintains regulatory approvals in major pharmaceutical markets:
| Region | Regulatory Authority | Approval Year |
|---|---|---|
| United States | FDA | 2018 |
| France | ANSM | 2017 |
| Japan | PMDA | 2016 |
Additional regulatory filing capabilities include:
- European Union
- China
Find a cosmetic lab in France
Click below to see the profile of a cosmetic lab similar to Ecoxtract in France.
